Short Interest in Valneva SE (NASDAQ:VALN) Drops By 49.2%

Valneva SE (NASDAQ:VALN - Get Free Report) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 9,900 shares, a decrease of 49.2% from the March 31st total of 19,500 shares. Based on an average daily volume of 78,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company's shares are short sold.

Institutional Investors Weigh In On Valneva

Hedge funds and other institutional investors have recently bought and sold shares of the company. ABC Arbitrage SA purchased a new stake in Valneva during the fourth quarter valued at approximately $84,000. GAMMA Investing LLC purchased a new position in Valneva in the 1st quarter worth $94,000. Finally, Wells Fargo & Company MN raised its stake in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after acquiring an additional 30,859 shares during the last quarter. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Price Performance

Shares of VALN opened at $7.04 on Monday. The company has a 50 day moving average price of $6.92 and a 200-day moving average price of $5.69. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The stock has a market capitalization of $588.38 million, a PE ratio of -54.12 and a beta of 1.85. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The business had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. Equities analysts predict that Valneva will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Guggenheim dropped their target price on shares of Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, March 24th. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.